Washington: More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that the number will increase by nearly 27 per cent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott Laboratories on Tuesday announced CE Marking (Conformite Europeenne) for the Abbott Architect HbA1c (IA) Assay.
Glycated haemoglobin, also known as HbA1c, is a form of haemoglobin used primarily to monitor long-term diabetes control. This helps physicians understand how well the patient’s diabetes is being managed from a treatment or dosing perspective. The HbA1c test differs from a patient-administered blood glucose test, which takes a snapshot of a patient’s blood sugar level at a moment in time. The HbA1c test must be performed on a laboratory instrument.
Laboratories are seeing an increase of HbA1c testing volumes worldwide due to the rise in patients with diabetes. The Abbott Architect HbA1c assay is a fully automated chemiluminescent immunoassay to help laboratories manage the increased demand and offer rapid results to physicians. With a simple blood test, the Abbott Architect HbA1c (IA) Assay provides a result to the physician in just 36 minutes. It also demonstrates a good correlation to the gold standard (high performance liquid chromatography), which provides confidence in the accuracy and reproducibility of patient results.
“Abbott’s Architect HbA1c (IA) Assay allows for consistent and accurate testing of HbA1c,” said Brian Blaser, executive vice president, diagnostics products, Abbott. “With this test, health care providers can now confidently measure their patients’ management of diabetes and use this information to potentially improve treatment decisions.”
The new assay is performed on the Architect immunoassay systems and is available in several European countries, Asia Pacific, Latin America, Japan, Africa, Middle East and India, pending country registration.
The Architect HbA1c (IA) assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of per cent haemoglobin A1c (HbA1c) in human whole blood on the Architect i System. Per cent HbA1c measurements are used in the clinical management of diabetes to assess long-term diabetic control.
Abbott has developed and launched a series of Architect analysers that are delivering flexibility, automation, and convenience to clinical laboratory. A truly integrated portfolio of immunoassay and clinical chemistry instruments, Architect offers more than 170 assays and has features that minimize training and reduce inventory costs and sample contamination potential, which results in improved performance and outcomes for laboratories, physicians, and patients.
Abbott is a global leader in in vitro diagnostics and offers a range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices, and clinics. With more than 22,000 customers in more than 100 countries, Abbott’s diagnostic products offer customers automation, convenience, bedside testing, cost-effectiveness, and flexibility.